<DOC>
	<DOC>NCT00383214</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of Epratuzumab with standard treatments for patients with SLE.</brief_summary>
	<brief_title>Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<criteria>+ANA at screening BILAG Index B Level Activity in at least 2 body systems/organs Has SLE by ACR revised criteria (meets,&lt;4 criteria) Active Severe Lupus as defined by BILAG Index Level A in any body system or organ. Allergy to human antibodies or Murine.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Lupus,</keyword>
	<keyword>antibody,</keyword>
	<keyword>B-cell immunotherapy</keyword>
</DOC>